Cubist’s latest antibiotic won praise from a panel of FDA advisers, setting the stage for a likely approval and head-to-head competition with Pfizer’s blockbuster Zyvox. …read more Source: Cubist’s superbug drug clears FDA panel, lines up for Pfizer showdown
AstraZeneca isn’t due to move into its new Cambridge, U.K., headquarters for another two years, but the British giant is already laying the groundwork for open collaboration in the biomedical hub, signing a deep-seated deal with the government-run Medical Research Council to work on drug discovery. …read more Source: AstraZeneca cozies up to MRC scientists […]
Lexington, MA-based Curis says the FDA has lifted the partial clinical hold on CUDC-427, which was instituted after the death of a patient in a Phase I study of solid tumors and lymphoma. …read more Source: FDA lifts a partial hold on Curis cancer drug
The drug giant is pulling its application in Europe after concluding that the data didn’t paint a sufficiently positive portrait of overall survival benefits for patients–despite an improvement seen in progress-free survival. …read more Source: Glaxo scraps the ovarian cancer app for Votrient
Small-cap Australian biotech Prana Biotechnology set out to vanquish a biomarker for Alzheimer’s disease in a Phase II study of a lead drug pursuing an odd avenue in fighting the disease. This morning, when it acknowledged that the study was a bust, the rout of investors popped its stock price, pumped up in a speculative […]
No matter how badly a drug fails in Phase III, investigators and the companies that employ them often bend over backwards to highlight any positive sign of efficacy, no matter how weak the signal. And GlaxoSmithKline’s team at the American College of Cardiology meeting over the weekend was in full spin mode with their heart […]
Amgen widened its lead among competing drugmakers in a promising new field of cardio treatments on the strength of late-stage results in which its in-development drug lowered LDL cholesterol by as much as 75%. …read more Source: Amgen’s PCSK9 drug slashes ‘bad’ cholesterol in PhIII, stoking blockbuster hopes
…read more Source: Biogen wins FDA OK for long-acting hemophilia drug Alprolix
AstraZeneca has struck up a partnership with the Shenzhen University Health Science Center in Shanghai to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China’s aging population. …read more Source: AstraZeneca looks to China for kidney disease R&D
In the nearly 40 years since scientists first nailed down the Ebola virus, drug researchers have yet to commercialize an effective therapy for the deadly disease, a problem made worse by a lack of commercial promise and the relative rarity of outbreaks. …read more Source: Ebola still a tough target due to Big Pharma disinterest […]
